On June 24th, 2022 Rowpar was acquired by Arcadia Consumer Health Care. Arcadia provides simple, efficacious, high quality solutions to help you achieve the harmony of feeling good and looking good. The acquisition includes the ClōSYS Oral Care brand. Rowpar Pharmaceuticals Inc., remains a subsidiary of Arcadia Consumer Healthcare Inc.Continue reading
Author Archive: AZBio
First in Human Subjects Enrolled in Aqualung Therapeutics Phase 1A Study Evaluating Safety, Tolerability and Pharmacokinetics of ALT-100
TUCSON, AZ / ACCESSWIRE / July 5, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, announced today that their first two patients have been enrolled in the phase 1A healthy human volunteer Study. The data from this study will be used to understand and validate dosing and safety of the humanized monoclonal antibody therapeutic ALT-100 for future clinical trials that address diseases driven by unchecked inflammation.Continue reading
Substantial ROI Expected From Center for Advanced Molecular and Immunological Therapies
Economic estimates show a new University of Arizona Health Sciences center will positively impact job growth and enhance incomes and tax revenues.
The Center for Advanced Molecular and Immunological Therapies will provide staff, facilities, support and services to advance precision medicine while anchoring a biosciences innovation hub on the Phoenix Bioscience Core.
Publication Highlights Potential Clinical Applications of the HTG Transcriptome Panel in Bladder Cancer
TUCSON, Ariz., June 29, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced the customer publication of a peer reviewed journal article featuring the HTG Transcriptome Panel (HTP) less than one year after the breakthrough product’s commercial release.Continue reading
Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations
Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022.
New data from pooled analysis shows DecisionDx®-Melanoma can identify patients at a high risk of melanoma recurrence within a patient population deemed low risk (T1, ≤1mm) by traditional staging systems
- Survey of 400 dermatologic clinicians demonstrates how DecisionDx®-SCC results can lead to risk-aligned treatment plan changes for patients with high-risk squamous cell carcinoma
- Castle’s laboratory workflow for MyPath® Melanoma and DecisionDx® DiffDx®-Melanoma increased the reporting of clinically actionable results to over 99% in a performance cohort of 350 archival biopsy samples
Gene Variation May Be Early Indicator for Gastric Cancer
A new study identified a gene variation that could inform clinicians which patients are more susceptible to developing stomach cancer. Researchers at the University of Arizona Health Sciences are hoping to catch stomach cancer before it develops in at-risk patients. In a paper published in Gastroenterology, researchers identified a genetic variation that could help identify when patients with Helicobacter pylori are more likely to develop stomach cancer.Continue reading
Exact Sciences Showcases Breadth Of Early Detection And Treatment Guidance Portfolio With Multiple Data Presentations At ASCO 2022
Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, showcased new data supporting its cancer tests and treatment guidance tools in nine poster presentations and five e-abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3-7 in Chicago, Illinois.Continue reading
Immune recognition of self and non-self explored in new study
In a new study, Arizona State University researcher Joshua LaBaer and his colleagues explore components of the immune system known as autoantibodies. While they have been implicated as central players in a range of serious autoimmune diseases, the study observes that autoantibodies are also found in healthy individuals.Continue reading
Humabiologics and REGEMAT 3D partner to provide printable human-derived biomaterials to the European Market
Humabiologics, an industry leader in providing human-derived biomaterials for regenerative medicine, and REGEMAT 3D, a company at the forefront of personalized biofabrication solutions, announce they have entered into a non-exclusive distribution agreement to respond to the growing demand and serve a broader life sciences customer base of industry partners and academic institutions in the European bioprinting and drug testing market.Continue reading
Moreno to Lead All of Us Research Program University of Arizona-Banner Health
Dr. Francisco Moreno will direct the program’s vision and operations as the primary liaison between the UArizona-Banner team and the National Institutes of Health.Continue reading